Citation: Khan F, et al. Catheter-Based Renal Denervation in Patients with Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL HTN-OFF MED):A Randomised, Sham-Controlled, Proof-of-Concept Trial. Ann Med Health Sci Res.2018;8:62-63

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Abstract

Increasing burden of hypertension worldwide has stirred a lot of research work regarding the establishment of its effective treatment. The clinical trial ‘Catheter based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomized, sham-controlled, proof-of-concept trial’ published in ‘The Lancet’ (2017; 7: 0140-673) has explored a procedure called ‘Renal Denervation’ as a possible treatment for resistant hypertension. We read this article with great interest and congratulate the researchers for confirming the efficacy of renal denervation in patients with mild to moderate hypertension.

Keywords

Resistant hypertension; Catheter Based Renal Denervation; Lifestyle Modification; Anti-Hypertensive Medications; Non-Compliance

Letter to Editor

We have read, with great interest, the original article titled ‘Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial’ published in ‘The Lancet’ (2017; 7: 0140- 6736). [1] In this clinical trial efficacy of renal denervation in patients with mild to moderate resistant Hypertension has been demonstrated. Although previous trial ‘SYMPLICITY HTN-3’ [2] had confirmed the efficacy of renal denervation by keeping the patients ‘OFF-ANTI HYPERTENSIVE MEDICATIONS’ and overcoming other limitations that were incriminated to be the probable causes of negative results of previous trials. [3] No adverse effects of the procedure occurred during or at the end of the clinical trial.

We want to share our following views regarding this clinical trial. Results of a clinical trial with large sample size and that including patients from different ethnicities and races have a greater impact on medical literature as compared to one with a small sample size. Results of such studies can be easily applied and are reliable. But during this clinical trial, the procedure of renal denervation was conducted only in 80 patients, which warrant further research related to this procedure. Although no adverse effects or complications of the method occurred at the end of this trial, many potential long-term complications that could have been detailed by long duration follow up might have been missed due to short follow up of three months. The study also didn’t elaborate the potential adverse outcomes of the process and that how the risk factors of this process can be minimized as for example the theoretical risk of renal vessel damage.

As there is no universal protocol regarding the modus operandi of renal denervation, the difference in the techniques and strategies of proceduralists while carrying out the procedure should have affected the results, which has also not been detailed in the study. Furthermore, there is no method to determine the degree of nerve destruction after performing this procedure and the differences in the extent of denervation among the candidates of research that had undergone this procedure, might have affected the outcome.

Although renal denervation is an evolutionary treatment option for resistant hypertension, the establishment of indications, contraindications, cost-effectiveness and potential short-, and long-term adverse effects is necessary before establishing universal protocol and guidelines of the procedure.

Hypertension is a leading cause of mortality and morbidity worldwide. Given to the increasing prevalence of hypertension multiple studies and clinical trials have been and are being conducted to develop effective and convenient treatment of hypertension. The overall prevalence of hypertension in adult population worldwide was found to be 26.4% in 2000, whereas 29.2% of the adult population was estimated to develop Hypertension by 2025. [4] The overall prevalence of Hypertension in South East Asia is 27%. [5]

Although renal denervation can be a useful measure to control mild to moderate resistant hypertension in otherwise healthy patients, the establishment of the efficacy of the procedure in patients with co-morbidities and severe resistant hypertension would require further clinical trials. Moreover, in economically developing parts of the world like South East Asia, where health facilities and patient education are limited, the procedure of renal denervation would be challenging to carry out even in the patients with resistant hypertension. For example in our country, Pakistan, National Health Survey estimated that hypertension affects 18% of adults and 33% of adults above 45 years old. [6] Multiple factors like poor awareness, unhealthy diet, urbanization and sedentary lifestyle among others, have resulted in significant increase in the number of hypertensive patients, those with uncontrolled hypertension and those with hypertension associated complications. [7] On the other hand, among the patients who are on anti-hypertensive medications, a significant proportion of approximately 23% was found to be non-adherent to their treatment in one study conducted in leading hospitals dealing with a substantial burden of cardiovascular diseases in Karachi, Pakistan. [8] Multiple factors like younger age, poor awareness and symptomatic treatment are attributed as adversely affecting the adherence to anti-hypertensive medications. [8] In Pakistan, like other developing countries, a significant number of patients are uneducated, and even a higher proportion of the population is unaware of the risk factors for the disease. Under the conditions as discussed above a considerable amount of time, energy and economic stability are necessary before introducing renal denervation as a treatment option for uncontrolled or resistant hypertension in the developing world. Before considering renal denervation as an alternative treatment for resistant hypertension, improving availability and quality of present therapy is necessary. Also before making it a standard treatment for resistant hypertension, more clinical trials should scrupulously assess it for adverse effects.

We think that under the circumstances as mentioned above lifestyle modification, [9] high-dose anti-hypertensive regimen, patient education and adequate adherence to medications would still be a superior mode of treatment for resistant hypertension.

Conflict of Interest

All authors disclose that there was no conflict of interest.

REFERENCES

1. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet. 2017; 390: 2160-2170.
2. Bhatt DL, Kandzari DE, O'neill WW, D'agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine. 2014; 370: 1393-1401.
3. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal. 2014; 36: 219-227.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. The Lancet. 2005; 365: 217-223.
5. Neupane D, McLachlan CS, Sharma R, Gyawali B, Khanal V, Mishra SR, et al. Prevalence of hypertension in member countries of South Asian Association for Regional Cooperation (SAARC). Medicine. 2014; 93: e74.
6. Saleem F, Dua J, Hassali A, Shafie A. Hypertension in Pakistan: Time to take some serious action. British Journal of General Practice. 2010; 60: 449-450.
7. Nielsen J, Shrestha A, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. Journal of Human Hypertension. 2016; 31: 14-21.
8. Hashmi SK, Afridi MB, Abbas K, Sajwani RA, Saleheen D, Frossard PM, et al. Factors associated with adherence to anti-hypertensive treatment in Pakistan. PLoS ONE. 2007; 2: e280.
9. Beilin L. Lifestyle and hypertension. American Journal of Hypertension. 1999; 12: 934-945.